Personalized medicine firm Viome and Scripps Research launched a collaboration to develop and clinically validate a non-invasive RNA-based test for early detection of precancerous colon polyps. Utilizing stool and saliva samples, the study will enroll 1,000 participants undergoing routine colonoscopies at Scripps Health. Viome aims to leverage AI to identify microbiome biomarkers indicative of cancer risk, enabling accessible home collection without invasive procedures. The initiative plans FDA approval pursuit and publication of biomarkers to advance colorectal cancer prevention strategies.